



1648

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re: Application of:

FANG FANG

Serial No.: 09/555,446

Filed: AUGUST 16, 2000

Title: **MULTIVALENT RECOMBINANT  
ANTIBODIES FOR TREATING HRV  
INFECTIONS**

) Group Art Unit: 1648

) Examiner: Latrice Vaghn

) CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

) I hereby certify that this correspondence and all marked  
) attachments are being deposited with the United States  
) Postal Service in an envelope addressed to Director of  
) Patents, U.S. Patent and Trademark Office, Mail Stop  
) DD, P.O. Box 1450, Alexandria, VA 22313-1450

) on October 15, 2003.

)   
) Karyn F. Massie

**TRANSMITTAL LETTER**

Director of Patents

MS: DD

P.O. Box 1450

Alexandria, VA 22313-1450


Sir:

Transmitted herewith for filing are the following:

1. Information Disclosure Statement;
2. Authorization to Pay Fees;
3. PTO Form 1449;
4. Cited References; and
5. Return Postcard.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 

Robert M. Bedgood, Ph.D.

Registration No. 43,488

Tel.: (858) 509-4065

Fax: (858) 509-4010



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF )

FANG, Fang )

Appln. No.: 09/555,446 )

Filed: August 16, 2000 )

Title: MULTIVALENT RECOMBINANT )  
ANTIBODIES FOR TREATING HRV )  
INFECTIONS )

Atty. Docket No.: 014357-0278749 )

Examiner: L. Vaghn

Group Art Unit: 1648

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along  
with any paper referred to as being attached) is  
being mailed to Addressee by service of the  
United States Postal Service addressed to:

Director of Patents

Mail Stop: DD

P.O. Box 1450

Alexandria, VA 22313-1450

By: Karyn F. Massie

Karyn F. Massie

Date: 10/15/03

INFORMATION DISCLOSURE STATEMENT

Director of Patents

Mail Stop: DD

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed citations submitted in  
compliance with the duty of disclosure as defined in 37 C.F.R. §1.56.

Request Under Rule 37 C.F.R. §97(e)(1): A first action on the merits has been  
issued in this matter, please accept this Information Disclosure Statement under Rule 37 C.F.R.  
§97(e)(1) because each item of information contained in the information disclosure statement  
was first cited in a communication from a foreign patent office in a counterpart foreign  
application not more than three months prior to the filing of this information disclosure  
statement. The Commissioner is hereby authorized to charge any future fee required to the  
deposit account identified in the attached "Authorization to Pay and Petition for Acceptance of

Any Necessary Fees" to cover this fee and proceed to consider this Information Disclosure Statement.


This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.

Respectfully submitted,

PILLSBURY WINTHROP LLP




Robert M. Bedgood, Ph.D.  
Reg. No 43,488  
Tel. No. (858) 509-4065  
Fax No. (858) 509-4010  
11682 El Camino Real  
Suite 200  
San Diego, CA 92130-2593  
(619) 234-5000



**AUTHORIZATION TO PAY AND PETITION FOR ACCEPTANCE OF  
ANY NECESSARY FEES**

If any charges or fees must be paid in connection with the foregoing communication (including but not limited to the payment of an extension fee or issue fee), or if any overpayment is to be refunded in connection with the above-identified application, any such charges or fees, or any such overpayment may be respectively paid out of, or into, our Deposit Account No. 50-2212 under **Reference No.: 014357-0278749.**

Respectfully submitted,  
PILLSBURY WINTHROP LLP

  
Robert M. Bedgood, Ph.D  
Reg. No. 43,488  
11682 El Camino Real, Suite 200  
San Diego, CA 92130  
Tel: (858) 509-4065  
Fax: (858) 509-4010



FORM PTO-1449 (modified)  
U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office

To:

Atty.  
Dkt. No.

M#

Client Ref.

0278749

014357

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

Applicant: **FANG, Fang**

Appln. No.: **09/555,446**

Filing Date: **August 16, 2000**

Date: Oct ber **15**, 2003

Page

**1**

of **1**

Examiner: **Wortman, D.**

Group Art Unit: **1648**

**U.S. PATENT DOCUMENTS**

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						
	DR						
	ER						

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Encl osed	No	Enclose	No
	FR	WO 91/16927	11/1991	PCT	Adair	Y			
	GR								
	HR								

**OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)**

	IR	Foote, et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <i>J. mol. Biol.</i> (1992) Vol. 224, pp. 487-490.				Y			
	JR	PCT International Search Report, dated September 8, 2003 for PCT/US 02/23002				Y			

Examiner

Date Considered:

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.